Navigation Links
Healthcare Industry Leader Virginia Rybski Remembered
Date:5/13/2013

SCOTTSDALE, Ariz., May 13, 2013 /PRNewswire/ -- Regenesis Biomedical, Inc., a medical technology company focused on tissue regeneration, announced today that CEO Virginia Rybski lost her battle with pancreatic cancer.  Virginia was compassionately dedicated to her family, colleagues, patients and faith.

(Photo:  http://photos.prnewswire.com/prnh/20130513/LA13153)

(Logo:  http://photos.prnewswire.com/prnh/20120109/LA31405LOGO)

"We celebrate the privilege to have worked with such a talented leader, who was the driving force behind Regenesis' success," said John Voris , Chairman of the Board of Directors.  "Virginia's legacy includes a capable and dedicated management team that remains intact.  They are committed to achieving her vision of reaching patients in need of pain relief with the Provant® Therapy System."  

Ms. Rybski served Regenesis most recently as President, Chief Executive Officer and Board Director.  She combined 35 years experience founding and building emerging bioscience companies, by developing and commercializing numerous advanced-technology healthcare products.  Virginia earned a Bachelor of Arts in Molecular Biology from the University of North Carolina, and a Masters in Hospital Administration from the University of Phoenix.  She served on the Board of Directors for AdvaMed, the advanced medical technology association, as well as serving on the Emerging Growth Company Council, the Payment Advisory Work Group, and the Wound Sector Group.  She also served on the Board of Directors for AZBIO, the Arizona biotechnology and medical device association.

Virginia is survived by her husband Tom, and daughters Savannah and Olivia.  Her family provided the opportunity to support pancreatic research, through the Pancreatic Cancer Action Network at https://netcommunity.pancan.org/sslpage.aspx?pid=218

Regenesis will soon make an announcement regarding the CEO succession plan.

About Regenesis Biomedical

Regenesis Biomedical, Inc. is a privately held medical technology company focused on developing and marketing noninvasive regenerative medicine products.  Regenesis developed, patented, and now markets the Provant Therapy System.  Our customers include health care facilities, acute care hospitals, long-term acute care hospitals, skilled nursing facilities, rehabilitation centers, home health care agencies, and outpatient clinics.

About the Provant® Therapy System

Provant uses pulsed radio frequency energy (PRFE) to facilitate reduction of the pain and edema associated with post-operative, superficial soft tissues.

Contact: Regenesis Biomedical, Inc.
Scott Robey , Vice President Marketing
www.regenesisbio.com
480-970-4970 phone


'/>"/>
SOURCE Regenesis Biomedical, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CitiusTechs BI-Clinical Platform for Healthcare BI & Analytics Receives NCQA HEDIS Certification
2. Actavis Cancels Presentation at Bank of America Merrill Lynch Healthcare Conference
3. Isis Pharmaceuticals to Present at the 2013 UBS Global Healthcare Conference
4. Lexicon To Present At The Bank of America Merrill Lynch Healthcare Conference
5. Healthcare Corporation of America Sets Date for Release of its First-Quarter Results and Conference Call
6. Bayer Employee Named Rising Star by Healthcare Businesswomens Association
7. Maxim Healthcare Services Names National Caregiver of the Year Winner
8. Allied Healthcare Products Reports Loss On Depressed Sales
9. BidMed Awarded Equipment Liquidation and Related Services Agreement with the Premier Healthcare Alliance
10. Millennium HealthCare Signs Exclusive Distribution Agreement with Heart Smart Inc.
11. Cynosure to Present at UBS Global Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/7/2017)...  Novavax, Inc., (Nasdaq: NVAX ) today announced ... of its RSV F protein recombinant nanoparticle vaccine candidate (RSV ... published in the journal Vaccine (the ... scientific conferences). The Company previously announced top line results ... the RSV F Vaccine with the goal of protecting infants ...
(Date:6/2/2017)... , June 2, 2017  NxStage Medical, Inc. (Nasdaq: ... care, today announced new findings demonstrating positive biochemical outcomes ... System One™. The data will be presented at ... Madrid, Spain . ... Improve Home Dialysis Network in Europe ...
(Date:5/29/2017)...  Cellect Biotechnology Ltd. (NASDAQ: APOP ; TASE: ... functional selection of stem cells, today provided a corporate ... ended March 31 st , 2017. ... first quarter of 2017," said Dr. Shai Yarkoni, Chief ... treatment of the first blood cancer patient in the ...
Breaking Medicine Technology:
(Date:6/23/2017)... (PRWEB) , ... June 23, 2017 , ... ... Breast Cancer Conference from Sept. 18 to 20. , The two-day conference is ... subtype with the goal of improving patients’ lives and eliminating racial breast cancer-related ...
(Date:6/23/2017)... Monica, CA (PRWEB) , ... June 23, 2017 , ... ... as the endorsed amalgam separator supplier for CDA members. As part of the amalgam ... reduced price of $99, saving more than $400 off the retail value. This partnership ...
(Date:6/23/2017)... San Francisco, CA (PRWEB) , ... June 23, 2017 , ... ... Conference on 26th June, 2017 from 9 am to 3 pm to present to ... curriculum. The program is an original curriculum project led by The Health Improvement ...
(Date:6/23/2017)... Gilmer, TX (PRWEB) , ... June 23, 2017 , ... ... consultations to residential and business clients throughout eastern Texas, is announcing the launch of ... , Recent breast cancer statistics in the United States reveal that an estimated ...
(Date:6/22/2017)... Miami, FL (PRWEB) , ... June 22, 2017 , ... ... has received more than $245,000 in grant funding to support its programs focused on ... recently, Branches, Inc. was awarded a grant by the Foundation of $15,000 to support ...
Breaking Medicine News(10 mins):